BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hadler SC, Margolis HS. Viral Hepatitis. In: Evans AS, editor. Viral Infections of Humans. Boston: Springer US; 1995. pp. 351-91. [DOI: 10.1007/978-1-4615-8138-3_13] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
Number Citing Articles
1 . Hepatitis A Virus. Transfus Med Hemother 2005;32:167-73. [DOI: 10.1159/000087617] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
2 Vento S. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. J Viral Hepat. 2000;7 Suppl 1:7-8. [PMID: 10866837 DOI: 10.1046/j.1365-2893.2000.00019.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 1.7] [Reference Citation Analysis]
3 Almasio PL, Amoroso P. HAV infection in chronic liver disease: a rationale for vaccination. Vaccine 2003;21:2238-41. [DOI: 10.1016/s0264-410x(03)00139-7] [Cited by in Crossref: 37] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
4 Levy MJ, Herrera JL, Dipalma JA. Immune globulin and vaccine therapy to prevent hepatitis a infection. The American Journal of Medicine 1998;105:416-23. [DOI: 10.1016/s0002-9343(98)00296-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
5 Van Herck K, Van Damme P. Prevention of hepatitis A by Havrix: a review. Expert Rev Vaccines 2005;4:459-71. [PMID: 16117704 DOI: 10.1586/14760584.4.4.459] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 2.0] [Reference Citation Analysis]
6 Keeffe E. Hepatitis A in patients with chronic liver disease - severity of illness and prevention with vaccination. J Viral Hepat 2000;7 Suppl 1:15-7. [PMID: 10870175 DOI: 10.1046/j.1365-2893.2000.00016.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
7 Jacobs RJ, Rosenthal P, Meyerhoff AS. Cost effectiveness of hepatitis A/B versus hepatitis B vaccination for US prison inmates. Vaccine 2004;22:1241-8. [PMID: 15003653 DOI: 10.1016/j.vaccine.2003.09.018] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
8 Durlach R, Laugas S, Freuler CB, Rodriguez VE, Costa M. Ten-year persistence of antibody to hepatitis B surface antigen in healthcare workers vaccinated against hepatitis B virus, and response to booster vaccination. Infect Control Hosp Epidemiol 2003;24:773-6. [PMID: 14587943 DOI: 10.1086/502132] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
9 Floreani A, Baldo V, Cristofoletti M, Renzulli G, Valeri A, Zanetti C, Trivello R. Long-term persistence of anti-HBs after vaccination against HBV: an 18 year experience in health care workers. Vaccine 2004;22:607-10. [DOI: 10.1016/j.vaccine.2003.09.001] [Cited by in Crossref: 93] [Cited by in F6Publishing: 78] [Article Influence: 5.5] [Reference Citation Analysis]
10 Péchevis M, Khoshnood B, Buteau L, Durand I, Piquard Y, Lafuma A. Cost-effectiveness of hepatitis A vaccine in prevention of secondary hepatitis A infection. Vaccine. 2003;21:3556-3564. [PMID: 12922083 DOI: 10.1016/s0264-410x(03)00424-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
11 François G, Hallauer J, Van Damme P. Hepatitis B vaccination: how to reach risk groups. Vaccine 2002;21:1-4. [DOI: 10.1016/s0264-410x(02)00440-1] [Cited by in Crossref: 32] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]